| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Trial |
The anti-asthmatic effects of theophylline may supplement those of inhaled steroids in asthma. The aim of the present trial was to study how the addition of theophylline compares to doubling the dose of inhaled steroid in asthmatics who remain symptomatic on beclomethasone dipropionate (BDP) 400 microg x day(-1). The trial was designed as a randomized, double-blind, parallel-group study in several European countries. Sixty nine patients were treated for 6 weeks with theophylline plus BDP 400 microg x day(-1), compared to 64 patients treated with BDP 800 micro x day(-1). The mean+/-SD serum theophylline concentration was 10.1+/-4.2 mg x L(-1). Lung function measurements were made throughout the study and patients kept daily records of peak expiratory flow (PEF), symptoms and salbutamol usage. Forced expiratory volume in one second and PEF at week 6 were significantly increased by both treatments (p<0.01). PEF variability was reduced by about 30% in both groups. There were significant improvements in asthma symptoms and rescue medication use (p<0.001). There were no significant differences between the treatment groups. The study demonstrated clinical equivalence of theophylline plus beclomethasone dipropionate 400 microg x day(-1) and beclomethasone dipropionate 800 microg x day(-1) in patients whose asthma is not controlled on beclomethasone dipropionate 400 microg x day(-1). The results support the use of theophylline as a steroid-sparing agent. The combination of low-dose inhaled steroid plus theophylline is a suitable treatment for moderate asthma.
This article has been cited by other articles:
|
|
 |
|
  E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The American Lung Association Asthma Clinical Rese Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 235 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes Theophylline in Chronic Obstructive Pulmonary Disease: New Horizons Proceedings of the ATS, November 1, 2005; 2(4): 334 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes, I. M. Adcock, and K. Ito Histone acetylation and deacetylation: importance in inflammatory lung diseases Eur. Respir. J., March 1, 2005; 25(3): 552 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes and I. M. Adcock How Do Corticosteroids Work in Asthma? Ann Intern Med, September 2, 2003; 139(5_Part_1): 359 - 370. [Full Text] [PDF]
|
|
|
|
 |
|
 R H Green, C E Brightling, I D Pavord, and A J Wardlaw Management of asthma in adults: current therapy and future directions Postgrad. Med. J., May 1, 2003; 79(931): 259 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes Theophylline: New Perspectives for an Old Drug Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 813 - 818. [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Dempsey, S. J. Fowler, A. Wilson, G. Kennedy, and B. J. Lipworth Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma* Chest, July 1, 2002; 122(1): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ito, S. Lim, G. Caramori, B. Cosio, K. F. Chung, I. M. Adcock, and P. J. Barnes A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression PNAS, June 25, 2002; 99(13): 8921 - 8926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Lipworth, F. Chung, P. Barnes, and S. Lim EFFECTS OF THEOPHYLLINE ON AIRWAY EOSINOPHILS Am. J. Respir. Crit. Care Med., March 15, 2002; 165(6): 845 - 845. [Full Text] [PDF]
|
|
|
|
|
|
P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids Eur. Respir. J., January 1, 2002; 19(1): 182 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]
|
|
|
|
|
|
S. LIM, K. TOMITA, G. CARRAMORI, A. JATAKANON, B. OLIVER, A. KELLER, I. ADCOCK, K. F. CHUNG, and P. J. BARNES Low-dose Theophylline Reduces Eosinophilic Inflammation but Not Exhaled Nitric Oxide in Mild Asthma Am. J. Respir. Crit. Care Med., July 15, 2001; 164(2): 273 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.F. Rabe and D.T. Schmidt Pharmacological treatment of asthma today Eur. Respir. J., July 2, 2001; 18(34_suppl): 34S - 40s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lim, A. Jatakanon, D. Gordon, C. Macdonald, K. F. Chung, and P. J Barnes Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice Thorax, October 1, 2000; 55(10): 837 - 841. [Abstract] [Full Text]
|
|
|
|
 |
|
 The use of inhaled corticosteroids in adults with asthma DTB, January 1, 2000; 38(1): 5 - 8. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
